20.85
price down icon2.89%   -0.62
after-market Handel nachbörslich: 20.85
loading

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

pulisher
03:40 AM

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN

03:40 AM
pulisher
Apr 05, 2026

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com

Apr 05, 2026
pulisher
Apr 04, 2026

BCAX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st

Apr 03, 2026
pulisher
Apr 03, 2026

Bicara Therapeutics Announces Inducement Grant - National Today

Apr 03, 2026
pulisher
Apr 03, 2026

New Bicara hire gets stock option for 44,175 shares at $20.50 - stocktitan.net

Apr 03, 2026
pulisher
Apr 03, 2026

Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN

Apr 03, 2026
pulisher
Apr 02, 2026

HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - marketbeat.com

Apr 02, 2026
pulisher
Apr 02, 2026

Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa

Apr 02, 2026
pulisher
Apr 01, 2026

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com

Apr 01, 2026
pulisher
Apr 01, 2026

Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget

Apr 01, 2026
pulisher
Apr 01, 2026

Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget

Apr 01, 2026
pulisher
Apr 01, 2026

Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat

Apr 01, 2026
pulisher
Apr 01, 2026

Bicara Therapeutics stock hits 52-week high, reaching $20.42 - Investing.com

Apr 01, 2026
pulisher
Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail

Apr 01, 2026
pulisher
Apr 01, 2026

Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN

Apr 01, 2026
pulisher
Mar 31, 2026

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - Seeking Alpha

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - marketbeat.com

Mar 31, 2026
pulisher
Mar 31, 2026

Wells Fargo Maintains Rating on BCAX, Increases Price Target to - gurufocus.com

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - marketbeat.com

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - marketbeat.com

Mar 31, 2026
pulisher
Mar 31, 2026

Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat

Mar 31, 2026
pulisher
Mar 31, 2026

BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - GuruFocus

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 31, 2026
pulisher
Mar 31, 2026

HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - marketbeat.com

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 31, 2026
pulisher
Mar 31, 2026

H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK

Mar 31, 2026
pulisher
Mar 31, 2026

H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa

Mar 31, 2026
pulisher
Mar 31, 2026

Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Mar 31, 2026
pulisher
Mar 31, 2026

Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK

Mar 31, 2026
pulisher
Mar 31, 2026

Bicara Q4 2025 slides: breakthrough designation, pivotal study data By Investing.com - Investing.com South Africa

Mar 31, 2026
pulisher
Mar 31, 2026

Value Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Key Lessons & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics (Nasdaq: BCAX) outlines pivotal ficerafusp alfa cancer program - stocktitan.net

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Inc. Files 8-K with SEC Detailing Q4 2025 Financials and Corporate Updates - Minichart

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Q4 2025 slides: breakthrough designation, pivotal study data - Investing.com

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Q4 Earnings Call Highlights - marketbeat.com

Mar 30, 2026
pulisher
Mar 30, 2026

Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data By Investing.com - Investing.com Australia

Mar 30, 2026
pulisher
Mar 30, 2026

Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data - Investing.com Australia

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics 2025 Financial Update - AlphaStreet

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics reports fourth quarter and full year 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results - marketbeat.com

Mar 30, 2026
pulisher
Mar 30, 2026

Cash runway to 2029 as Bicara (NASDAQ: BCAX) advances Phase 3 - stocktitan.net

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Inc. initiates Phase 3 trial with 1500 mg QW dose for FORTIFI-HN01 - Traders Union

Mar 30, 2026
pulisher
Mar 30, 2026

Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara moves head and neck cancer drug into Phase 3 after dose pick - stocktitan.net

Mar 30, 2026
pulisher
Mar 30, 2026

Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada

Mar 30, 2026
pulisher
Mar 29, 2026

Aug Gainers: What are analysts price targets for Bicara Therapeutics IncQuarterly Portfolio Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Mar 29, 2026
$48.77
price down icon 0.87%
$27.88
price down icon 1.59%
$47.32
price down icon 2.57%
$91.28
price up icon 0.11%
ONC ONC
$302.49
price down icon 2.67%
$163.81
price up icon 0.85%
Kapitalisierung:     |  Volumen (24h):